ViroCyt Adds New Funding

Denver-based ViroCyt, a developer of technology aimed at helping researchers develop therapies and vaccines from viruses, has raised a round of growth funding, the firm announced this morning. The funding brings its total raised in this round to $5M. ViroCyt said investors include High Country Venture along with a number of un-named angel networks. The new funds come as part of a round which had an initial close in November of 2012. ViroCyt is led by Robert Kline; the firm said its lead product is a technology created specifically to provide quantification of intact viral particles in minutes, used in therapies and vaccine development. More information »